BlackRock Investment Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$396K Buy
51,150
+891
+2% +$6.66K ﹤0.01% 3106
2016
Q3
$382K Buy
50,259
+2,806
+6% +$15.9K ﹤0.01% 3131
2016
Q2
$239K Buy
47,453
+720
+2% +$3.86K ﹤0.01% 3263
2016
Q1
$252K Buy
46,733
+820
+2% +$4.85K ﹤0.01% 3116
2015
Q4
$331K Buy
45,913
+345
+0.8% +$2.32K ﹤0.01% 3139
2015
Q3
$214K Sell
45,568
-771
-2% -$7.34K ﹤0.01% 3241
2015
Q2
$516K Buy
+46,339
New +$456K ﹤0.01% 3111

Other funds holding VCYT

BlackRock Investment Management's VCYT Position: Q4 2016 in Review

BlackRock Investment Management increased its Veracyte (VCYT) stake by 1.8% in Q4 2016, buying an estimated $6.66K and bringing the position to 51,150 shares worth $396K. The position accounts for ﹤0.01% of the portfolio, ranked #3106.

BlackRock Investment Management first reported a position in VCYT in Q2 2015 and has held it in 7 quarters since. The position peaked at $516K in Q2 2015. 74 funds tracked by Wall St. Rank hold VCYT as of Q4 2016.

  • BlackRock Investment Management held 51,150 shares of Veracyte worth $396K as of Q4 2016.
  • BlackRock Investment Management bought 891 Veracyte shares in Q4 2016, an estimated $6.66K.
  • Veracyte made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3106 holding.
  • BlackRock Investment Management first reported a position in Veracyte in Q2 2015 and has held it in 7 quarters since.
  • BlackRock Investment Management's Veracyte position peaked at $516K in Q2 2015.
  • 74 funds tracked by Wall St. Rank held Veracyte as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.